{"id":21385,"date":"2026-05-02T11:02:11","date_gmt":"2026-05-02T11:02:11","guid":{"rendered":"https:\/\/www.quantumrun.com\/consulting\/?p=21385"},"modified":"2026-05-02T11:04:03","modified_gmt":"2026-05-02T11:04:03","slug":"pfizer-statistics","status":"publish","type":"post","link":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/","title":{"rendered":"Pfizer Statistics 2026"},"content":{"rendered":"\n<style>\n\n.pfizer-stats-wrapper ul {\nmargin: 14px 0 20px 0;\npadding-left: 22px;\n}\n.pfizer-stats-wrapper ul li {\nmargin-bottom: 10px;\nfont-size: 16px;\ncolor: #2a2a2a;\n}\n.pfizer-stats-wrapper table {\nwidth: 100%;\nborder-collapse: collapse;\nmargin: 16px 0 8px 0;\nfont-size: 15px;\nbackground: #ffffff;\n}\n.pfizer-stats-wrapper th {\nbackground: #0a2540;\ncolor: #ffffff;\nfont-weight: 600;\npadding: 12px 14px;\ntext-align: center;\nborder: 1px solid #0a2540;\n}\n.pfizer-stats-wrapper td {\npadding: 11px 14px;\nborder: 1px solid #e1e5eb;\ntext-align: center;\ncolor: #2a2a2a;\n}\n.pfizer-stats-wrapper tr:nth-child(even) td {\nbackground: #f8fafc;\n}\n.pfizer-stats-wrapper .source-line {\nfont-size: 13px;\ncolor: #6b7280;\nmargin: 6px 0 24px 0;\nfont-style: italic;\n}\n.pfizer-stats-wrapper .chart-container {\nposition: relative;\nwidth: 100%;\nmax-width: 800px;\nmargin: 22px auto;\npadding: 18px;\nbackground: #ffffff;\nborder: 1px solid #e1e5eb;\nborder-radius: 6px;\nheight: 400px;\ndisplay: flex;\njustify-content: center;\nalign-items: center;\n}\n.pfizer-stats-wrapper details {\nborder: 1px solid #e1e5eb;\nborder-radius: 6px;\nmargin-bottom: 10px;\nbackground: #ffffff;\ntransition: all 0.25s ease;\n}\n.pfizer-stats-wrapper details[open] {\nbackground: #f8fafc;\nborder-color: #0a2540;\n}\n.pfizer-stats-wrapper summary {\npadding: 14px 18px;\ncursor: pointer;\ncolor: #0a2540;\nlist-style: none;\nposition: relative;\npadding-right: 42px;\n}\n.pfizer-stats-wrapper summary::-webkit-details-marker { display: none; }\n.pfizer-stats-wrapper summary::after {\ncontent: '+';\nposition: absolute;\nright: 18px;\ntop: 50%;\ntransform: translateY(-50%);\nfont-size: 22px;\nfont-weight: 400;\ncolor: #0a2540;\ntransition: transform 0.2s ease;\n}\n.pfizer-stats-wrapper details[open] summary::after { content: '\u2212'; }\n.pfizer-stats-wrapper summary:hover { background: #f1f5f9; border-radius: 6px; }\n.pfizer-stats-wrapper details p {\npadding: 0 18px 14px 18px;\nmargin: 0;\ncolor: #2a2a2a;\n}\n.pfizer-stats-wrapper a {\ncolor: #0a2540;\ntext-decoration: underline;\n}\n.pfizer-stats-wrapper a:hover { color: #1e40af; }\n.pfizer-stats-wrapper .citations {\nmargin-top: 28px;\npadding-top: 18px;\nborder-top: 1px solid #e1e5eb;\nfont-size: 14px;\n}\n.pfizer-stats-wrapper .citations p { margin-bottom: 8px; }\n@media (max-width: 600px) {\n.pfizer-stats-wrapper { padding: 14px; }\n.pfizer-stats-wrapper h2 { font-size: 22px; }\n.pfizer-stats-wrapper h3 { font-size: 18px; }\n.pfizer-stats-wrapper table { font-size: 13px; }\n.pfizer-stats-wrapper th, .pfizer-stats-wrapper td { padding: 8px 6px; }\n}\n<\/style>\n\n<div class=\"pfizer-stats-wrapper\">\n\n<p>Pfizer closed 2025 with $62.6 billion in revenue, ending the year as the world&#8217;s largest pharmaceutical company by sales despite a 2% decline. The company&#8217;s non-COVID portfolio grew 6% operationally, led by Eliquis, the Vyndaqel family, and Prevnar. This post breaks down the latest Pfizer Statistics 2026 covering revenue, top products, R&#038;D spending, employees, and geographic mix.<\/p>\n\n<h2>Key Pfizer Statistics 2026<\/h2>\n<ul>\n<li>Pfizer reported full-year 2025 revenue of $62.6 billion, a 2% decline from 2024.<\/li>\n<li>The non-COVID portfolio grew 6% operationally in 2025.<\/li>\n<li>R&#038;D spending hit $10.4 billion in 2025, plus $8.8 billion in business development deals.<\/li>\n<li>Pfizer ended 2025 with about 75,000 employees, down 7.4% year-over-year.<\/li>\n<li>U.S. revenue accounted for $37.1 billion in 2025, or 59% of the global total.<\/li>\n<\/ul>\n\n<h2>Pfizer Revenue 2025: Annual Performance<\/h2>\n<p>Pfizer recorded full-year 2025 revenue of $62.6 billion, down from $63.6 billion in 2024. The decline came mostly from lower COVID-19 product sales, while the rest of the portfolio kept growing. Foreign exchange added a $247 million boost.<\/p>\n\n<p>The company guided 2026 revenue between $59.5 billion and $62.5 billion, with COVID-19 products expected to contribute roughly $5 billion against $6.5 billion in 2025.<\/p>\n\n<table>\n<thead>\n<tr><th>Year<\/th><th>Revenue (USD)<\/th><th>Year-over-Year Change<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>2021<\/td><td>$81.3 billion<\/td><td>+92%<\/td><\/tr>\n<tr><td>2022<\/td><td>$100.3 billion<\/td><td>+23%<\/td><\/tr>\n<tr><td>2023<\/td><td>$58.5 billion<\/td><td>-42%<\/td><\/tr>\n<tr><td>2024<\/td><td>$63.6 billion<\/td><td>+7%<\/td><\/tr>\n<tr><td>2025<\/td><td>$62.6 billion<\/td><td>-2%<\/td><\/tr>\n<tr><td>2026 (guidance)<\/td><td>$59.5\u2013$62.5 billion<\/td><td>-1% to -5%<\/td><\/tr>\n<\/tbody>\n<\/table>\n<p class=\"source-line\">Source: Pfizer Q4 2025 Earnings Release<\/p>\n\n<div class=\"chart-container\"><canvas id=\"revenueChart\"><\/canvas><\/div>\n\n<h2>Pfizer Top-Selling Products 2025<\/h2>\n<p>Eliquis kept its spot as Pfizer&#8217;s top revenue driver in cardiovascular care, while the Vyndaqel family posted the strongest growth in the portfolio. Prevnar held steady, and Comirnaty bounced back in 2025 after softer prior quarters.<\/p>\n\n<table>\n<thead>\n<tr><th>Product<\/th><th>Category<\/th><th>2025 Revenue (Approx.)<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>Eliquis<\/td><td>Anticoagulant<\/td><td>$8.0 billion<\/td><\/tr>\n<tr><td>Vyndaqel family<\/td><td>Cardiovascular (ATTR-CM)<\/td><td>$6.7 billion<\/td><\/tr>\n<tr><td>Prevnar family<\/td><td>Vaccine<\/td><td>$6.5 billion<\/td><\/tr>\n<tr><td>Comirnaty<\/td><td>COVID-19 vaccine<\/td><td>$5.4 billion<\/td><\/tr>\n<tr><td>Paxlovid<\/td><td>COVID-19 antiviral<\/td><td>$2.0 billion<\/td><\/tr>\n<tr><td>Ibrance<\/td><td>Oncology<\/td><td>$4.4 billion<\/td><\/tr>\n<tr><td>Padcev<\/td><td>Oncology<\/td><td>$1.9 billion<\/td><\/tr>\n<\/tbody>\n<\/table>\n<p class=\"source-line\">Source: Pfizer Q4 2025 Earnings Release, SEC filings<\/p>\n\n<div class=\"chart-container\"><canvas id=\"productChart\"><\/canvas><\/div>\n\n<h2>Pfizer R&#038;D Spending and Pipeline Investment<\/h2>\n<p>R&#038;D spending reached $10.4 billion in 2025, slightly below the $10.8 billion spent in 2024. The reduction came from pipeline focus and lower compensation costs. Pfizer guided 2026 R&#038;D spending between $10.5 billion and $11.5 billion as it picks up investment in PD-1 x VEGF bispecific work and Metsera obesity programs.<\/p>\n\n<p>On top of internal R&#038;D, Pfizer spent about $8.8 billion on business development in 2025, including the Metsera acquisition and a 3SBio in-licensing deal.<\/p>\n\n<table>\n<thead>\n<tr><th>Year<\/th><th>R&#038;D Spending<\/th><th>% of Revenue<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>2021<\/td><td>$13.8 billion<\/td><td>17.0%<\/td><\/tr>\n<tr><td>2022<\/td><td>$11.4 billion<\/td><td>11.4%<\/td><\/tr>\n<tr><td>2023<\/td><td>$10.7 billion<\/td><td>18.3%<\/td><\/tr>\n<tr><td>2024<\/td><td>$10.8 billion<\/td><td>17.0%<\/td><\/tr>\n<tr><td>2025<\/td><td>$10.4 billion<\/td><td>16.7%<\/td><\/tr>\n<\/tbody>\n<\/table>\n<p class=\"source-line\">Source: Pfizer 10-K Filings, Macrotrends<\/p>\n\n<div class=\"chart-container\"><canvas id=\"rdChart\"><\/canvas><\/div>\n\n<h2>Pfizer Employees: Workforce Statistics 2026<\/h2>\n<p>Pfizer ended 2025 with about 75,000 employees, down from 81,000 a year earlier. That&#8217;s a 7.4% drop and the lowest headcount since 2017. The decline reflects the cost realignment program targeting roughly $4.5 billion in savings by year-end 2025, plus an additional $500 million in 2025.<\/p>\n\n<p>The company runs 37 manufacturing sites worldwide as of 2025.<\/p>\n\n<table>\n<thead>\n<tr><th>Year<\/th><th>Employees<\/th><th>Year-over-Year Change<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>2020<\/td><td>88,300<\/td><td>-4.4%<\/td><\/tr>\n<tr><td>2021<\/td><td>78,500<\/td><td>-11.1%<\/td><\/tr>\n<tr><td>2022<\/td><td>79,000<\/td><td>+0.6%<\/td><\/tr>\n<tr><td>2023<\/td><td>83,000<\/td><td>+5.1%<\/td><\/tr>\n<tr><td>2024<\/td><td>81,000<\/td><td>-2.4%<\/td><\/tr>\n<tr><td>2025<\/td><td>75,000<\/td><td>-7.4%<\/td><\/tr>\n<\/tbody>\n<\/table>\n<p class=\"source-line\">Source: Pfizer Annual 10-K Filings, StockAnalysis.com<\/p>\n\n<div class=\"chart-container\"><canvas id=\"employeeChart\"><\/canvas><\/div>\n\n<h2>Pfizer Revenue By Region 2025<\/h2>\n<p>The U.S. brought in $37.1 billion in 2025, or 59% of total revenue. International revenue from operations outside the U.S. came to $25.5 billion, with China and Japan called out as key markets in the company&#8217;s 10-K. Pfizer Statistics 2026 show emerging markets remain the smallest geographic segment.<\/p>\n\n<table>\n<thead>\n<tr><th>Region<\/th><th>2025 Revenue<\/th><th>Share of Total<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>United States<\/td><td>$37.1 billion<\/td><td>59.3%<\/td><\/tr>\n<tr><td>Developed Rest of World<\/td><td>$16.2 billion<\/td><td>25.9%<\/td><\/tr>\n<tr><td>Emerging Markets<\/td><td>$9.3 billion<\/td><td>14.9%<\/td><\/tr>\n<\/tbody>\n<\/table>\n<p class=\"source-line\">Source: Pfizer 2025 Annual Report (Form 10-K)<\/p>\n\n<div class=\"chart-container\"><canvas id=\"regionChart\"><\/canvas><\/div>\n\n<h2>Pfizer Market Cap and Stock Performance<\/h2>\n<p>Pfizer&#8217;s market cap stood at roughly $153 billion as of late April 2026, with the stock trading near $26.50. The market cap rose 9.3% over the prior 12 months. Pfizer paid a forward dividend yielding about 6.5%, one of the highest in big pharma.<\/p>\n\n<p>The company&#8217;s adjusted diluted EPS for 2025 came in at $3.21, beating its earlier guidance range of $2.80\u2013$3.00. For 2026, Pfizer reaffirmed adjusted EPS guidance of $2.80 to $3.00.<\/p>\n\n<h2>Pfizer Business Segments 2025<\/h2>\n<p>Pfizer reorganized into three segments in 2025: Biopharma (the main commercial business), PC1 (a separate biopharma unit), and Pfizer Ignite (services for biotech partners). Within Biopharma, Specialty Care grew 6% operationally in Q1 2025 while Primary Care fell 20% on Paxlovid declines.<\/p>\n\n<table>\n<thead>\n<tr><th>Segment<\/th><th>Q1 2025 Revenue<\/th><th>Operational Change<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>Primary Care<\/td><td>$5.7 billion<\/td><td>-20%<\/td><\/tr>\n<tr><td>Specialty Care<\/td><td>$4.0 billion<\/td><td>+6%<\/td><\/tr>\n<tr><td>Oncology<\/td><td>$3.7 billion<\/td><td>+7%<\/td><\/tr>\n<\/tbody>\n<\/table>\n<p class=\"source-line\">Source: Pfizer Q1 2025 Earnings Release<\/p>\n\n<h2>FAQs<\/h2>\n\n<details>\n<summary>What was Pfizer&#8217;s revenue in 2025?<\/summary>\n<p>Pfizer reported full-year 2025 revenue of $62.6 billion, down 2% from $63.6 billion in 2024. The decline came mainly from lower COVID-19 product sales, while non-COVID products grew 6% operationally.<\/p>\n<\/details>\n\n<details>\n<summary>What is Pfizer&#8217;s top-selling drug in 2025?<\/summary>\n<p>Eliquis was Pfizer&#8217;s top-selling drug in 2025, generating about $8 billion in revenue. The cardiovascular anticoagulant is co-marketed with Bristol-Myers Squibb and treats atrial fibrillation and blood clots.<\/p>\n<\/details>\n\n<details>\n<summary>How much does Pfizer spend on R&#038;D?<\/summary>\n<p>Pfizer spent $10.4 billion on internal R&#038;D in 2025, plus another $8.8 billion on business development deals including the Metsera acquisition. R&#038;D spending equals roughly 17% of total revenue.<\/p>\n<\/details>\n\n<details>\n<summary>How many employees does Pfizer have in 2026?<\/summary>\n<p>Pfizer had approximately 75,000 employees at the end of 2025, down from 81,000 a year earlier. The 7.4% decline reflects the company&#8217;s cost realignment program targeting $4.5 billion in savings.<\/p>\n<\/details>\n\n<details>\n<summary>What is Pfizer&#8217;s market cap in 2026?<\/summary>\n<p>Pfizer&#8217;s market cap was roughly $153 billion as of late April 2026, with the stock trading near $26.50. The company ranks among the world&#8217;s 110 most valuable public companies.<\/p>\n<\/details>\n\n<div class=\"citations\">\n<p><strong>Sources<\/strong><\/p>\n<p><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/0000078003\/000007800326000026\/pfe-20251231.htm\" rel=\"nofollow\">Pfizer 2025 Annual Report (Form 10-K), SEC Filing<\/a><\/p>\n<p><a href=\"https:\/\/annualreview.pfizer.com\/\" rel=\"nofollow\" class=\"external\">Pfizer 2025 Annual Review<\/a><\/p>\n<p><a href=\"https:\/\/www.macrotrends.net\/stocks\/charts\/PFE\/pfizer\/revenue\" rel=\"nofollow\" class=\"external\">Macrotrends Pfizer Revenue Data<\/a><\/p>\n<p><a href=\"https:\/\/stockanalysis.com\/stocks\/pfe\/employees\/\" rel=\"nofollow\" class=\"external\">StockAnalysis Pfizer Employee Statistics<\/a><\/p>\n<\/div>\n\n<\/div>\n\n<script src=\"https:\/\/cdn.jsdelivr.net\/npm\/chart.js\"><\/script>\n<script>\ndocument.addEventListener('DOMContentLoaded', function() {\nconst baseFont = \"Inter, Helvetica Neue, Arial, sans-serif\";\nChart.defaults.font.family = baseFont;\nChart.defaults.color = '#2a2a2a';\n\nnew Chart(document.getElementById('revenueChart'), {\ntype: 'bar',\ndata: {\nlabels: ['2021', '2022', '2023', '2024', '2025', '2026 (mid)'],\ndatasets: [{\nlabel: 'Revenue (USD Billion)',\ndata: [81.3, 100.3, 58.5, 63.6, 62.6, 61.0],\nbackgroundColor: '#0a2540',\nborderRadius: 4\n}]\n},\noptions: {\nresponsive: true,\nmaintainAspectRatio: true,\nplugins: {\ntitle: { display: true, text: 'Pfizer Annual Revenue 2021\u20132026', font: { size: 15, weight: '600' }, padding: { bottom: 14 } },\nlegend: { display: false }\n},\nscales: { y: { beginAtZero: true, title: { display: true, text: 'USD Billion' } } }\n}\n});\n\nnew Chart(document.getElementById('productChart'), {\ntype: 'bar',\ndata: {\nlabels: ['Eliquis', 'Vyndaqel', 'Prevnar', 'Comirnaty', 'Ibrance', 'Paxlovid', 'Padcev'],\ndatasets: [{\nlabel: '2025 Revenue (USD Billion)',\ndata: [8.0, 6.7, 6.5, 5.4, 4.4, 2.0, 1.9],\nbackgroundColor: ['#0a2540', '#1e5e8c', '#2d8db5', '#4eb3c7', '#7fc8d6', '#a8d8e0', '#c5e4e9'],\nborderRadius: 4\n}]\n},\noptions: {\nindexAxis: 'y',\nresponsive: true,\nmaintainAspectRatio: true,\nplugins: {\ntitle: { display: true, text: 'Pfizer Top Products by 2025 Revenue', font: { size: 15, weight: '600' }, padding: { bottom: 14 } },\nlegend: { display: false }\n},\nscales: { x: { beginAtZero: true, title: { display: true, text: 'USD Billion' } } }\n}\n});\n\nnew Chart(document.getElementById('rdChart'), {\ntype: 'line',\ndata: {\nlabels: ['2021', '2022', '2023', '2024', '2025'],\ndatasets: [{\nlabel: 'R&D Spending (USD Billion)',\ndata: [13.8, 11.4, 10.7, 10.8, 10.4],\nborderColor: '#0a2540',\nbackgroundColor: 'rgba(10, 37, 64, 0.08)',\ntension: 0.3,\nfill: true,\npointRadius: 5,\npointBackgroundColor: '#0a2540'\n}]\n},\noptions: {\nresponsive: true,\nmaintainAspectRatio: true,\nplugins: {\ntitle: { display: true, text: 'Pfizer R&D Spending 2021\u20132025', font: { size: 15, weight: '600' }, padding: { bottom: 14 } },\nlegend: { display: false }\n},\nscales: { y: { beginAtZero: false, title: { display: true, text: 'USD Billion' } } }\n}\n});\n\nnew Chart(document.getElementById('employeeChart'), {\ntype: 'line',\ndata: {\nlabels: ['2020', '2021', '2022', '2023', '2024', '2025'],\ndatasets: [{\nlabel: 'Employees',\ndata: [88300, 78500, 79000, 83000, 81000, 75000],\nborderColor: '#1e5e8c',\nbackgroundColor: 'rgba(30, 94, 140, 0.1)',\ntension: 0.3,\nfill: true,\npointRadius: 5,\npointBackgroundColor: '#1e5e8c'\n}]\n},\noptions: {\nresponsive: true,\nmaintainAspectRatio: true,\nplugins: {\ntitle: { display: true, text: 'Pfizer Global Headcount 2020\u20132025', font: { size: 15, weight: '600' }, padding: { bottom: 14 } },\nlegend: { display: false }\n},\nscales: { y: { beginAtZero: false, title: { display: true, text: 'Number of Employees' } } }\n}\n});\n\nnew Chart(document.getElementById('regionChart'), {\ntype: 'doughnut',\ndata: {\nlabels: ['United States', 'Developed Rest of World', 'Emerging Markets'],\ndatasets: [{\ndata: [37.1, 16.2, 9.3],\nbackgroundColor: ['#0a2540', '#2d8db5', '#7fc8d6'],\nborderWidth: 2,\nborderColor: '#ffffff'\n}]\n},\noptions: {\nresponsive: true,\nmaintainAspectRatio: true,\nplugins: {\ntitle: { display: true, text: 'Pfizer 2025 Revenue by Region (USD Billion)', font: { size: 15, weight: '600' }, padding: { bottom: 14 } },\nlegend: { position: 'bottom', labels: { padding: 14, font: { size: 13 } } }\n}\n}\n});\n});\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>Explore the latest Pfizer statistics for 2026, including revenue, top-selling drugs, R&#038;D spending, employee count, market cap, regional sales breakdown, and key pharmaceutical business trends shaping Pfizer\u2019s global performance.<\/p>\n","protected":false},"author":1,"featured_media":21386,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[245],"tags":[],"class_list":["post-21385","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pfizer Statistics 2026<\/title>\n<meta name=\"description\" content=\"Explore the latest Pfizer statistics for 2026, including revenue, top-selling drugs, R&amp;D spending, employee count, market cap, regional sales breakdown, and key pharmaceutical business trends shaping Pfizer\u2019s global performance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Statistics 2026\" \/>\n<meta property=\"og:description\" content=\"Explore the latest Pfizer statistics for 2026, including revenue, top-selling drugs, R&amp;D spending, employee count, market cap, regional sales breakdown, and key pharmaceutical business trends shaping Pfizer\u2019s global performance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/\" \/>\n<meta property=\"og:site_name\" content=\"Quantumrun Foresight\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-02T11:02:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-02T11:04:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/Pfizer-Statistics-e1777719714225.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1338\" \/>\n\t<meta property=\"og:image:height\" content=\"765\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Richard Jaimes\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Richard Jaimes\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/\"},\"author\":{\"name\":\"Richard Jaimes\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/person\\\/5a0afcb410d8e3137f58d5a201809011\"},\"headline\":\"Pfizer Statistics 2026\",\"datePublished\":\"2026-05-02T11:02:11+00:00\",\"dateModified\":\"2026-05-02T11:04:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/\"},\"wordCount\":804,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Pfizer-Statistics-e1777719714225.png\",\"articleSection\":[\"Companies\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/\",\"name\":\"Pfizer Statistics 2026\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Pfizer-Statistics-e1777719714225.png\",\"datePublished\":\"2026-05-02T11:02:11+00:00\",\"dateModified\":\"2026-05-02T11:04:03+00:00\",\"description\":\"Explore the latest Pfizer statistics for 2026, including revenue, top-selling drugs, R&D spending, employee count, market cap, regional sales breakdown, and key pharmaceutical business trends shaping Pfizer\u2019s global performance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Pfizer-Statistics-e1777719714225.png\",\"contentUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Pfizer-Statistics-e1777719714225.png\",\"width\":1338,\"height\":765,\"caption\":\"Pfizer statistics for 2026 covering $62.6 billion 2025 revenue (down 2%), Eliquis as top seller at $8 billion, $10.4 billion R&D spending, 75,000 employees (down 7.4%), U.S. at 59% of revenue, $153 billion market cap, and 2026 guidance of $59.5-$62.5 billion.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/pfizer-statistics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Companies\",\"item\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/companies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Pfizer Statistics 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#website\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/\",\"name\":\"Quantumrun Foresight\",\"description\":\"Thrive from future trends.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#organization\",\"name\":\"Quantumrun Foresight\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/cropped-con-logo-00.png\",\"contentUrl\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/cropped-con-logo-00.png\",\"width\":286,\"height\":55,\"caption\":\"Quantumrun Foresight\"},\"image\":{\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/#\\\/schema\\\/person\\\/5a0afcb410d8e3137f58d5a201809011\",\"name\":\"Richard Jaimes\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g\",\"caption\":\"Richard Jaimes\"},\"sameAs\":[\"https:\\\/\\\/www.quantumrun.com\\\/consulting\"],\"url\":\"https:\\\/\\\/www.quantumrun.com\\\/consulting\\\/author\\\/admin-stcons\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pfizer Statistics 2026","description":"Explore the latest Pfizer statistics for 2026, including revenue, top-selling drugs, R&D spending, employee count, market cap, regional sales breakdown, and key pharmaceutical business trends shaping Pfizer\u2019s global performance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/","og_locale":"en_US","og_type":"article","og_title":"Pfizer Statistics 2026","og_description":"Explore the latest Pfizer statistics for 2026, including revenue, top-selling drugs, R&D spending, employee count, market cap, regional sales breakdown, and key pharmaceutical business trends shaping Pfizer\u2019s global performance.","og_url":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/","og_site_name":"Quantumrun Foresight","article_published_time":"2026-05-02T11:02:11+00:00","article_modified_time":"2026-05-02T11:04:03+00:00","og_image":[{"width":1338,"height":765,"url":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/Pfizer-Statistics-e1777719714225.png","type":"image\/png"}],"author":"Richard Jaimes","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Richard Jaimes","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/#article","isPartOf":{"@id":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/"},"author":{"name":"Richard Jaimes","@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/person\/5a0afcb410d8e3137f58d5a201809011"},"headline":"Pfizer Statistics 2026","datePublished":"2026-05-02T11:02:11+00:00","dateModified":"2026-05-02T11:04:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/"},"wordCount":804,"commentCount":0,"publisher":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#organization"},"image":{"@id":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/Pfizer-Statistics-e1777719714225.png","articleSection":["Companies"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/","url":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/","name":"Pfizer Statistics 2026","isPartOf":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/#primaryimage"},"image":{"@id":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/Pfizer-Statistics-e1777719714225.png","datePublished":"2026-05-02T11:02:11+00:00","dateModified":"2026-05-02T11:04:03+00:00","description":"Explore the latest Pfizer statistics for 2026, including revenue, top-selling drugs, R&D spending, employee count, market cap, regional sales breakdown, and key pharmaceutical business trends shaping Pfizer\u2019s global performance.","breadcrumb":{"@id":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/#primaryimage","url":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/Pfizer-Statistics-e1777719714225.png","contentUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2026\/05\/Pfizer-Statistics-e1777719714225.png","width":1338,"height":765,"caption":"Pfizer statistics for 2026 covering $62.6 billion 2025 revenue (down 2%), Eliquis as top seller at $8 billion, $10.4 billion R&D spending, 75,000 employees (down 7.4%), U.S. at 59% of revenue, $153 billion market cap, and 2026 guidance of $59.5-$62.5 billion."},{"@type":"BreadcrumbList","@id":"https:\/\/www.quantumrun.com\/consulting\/pfizer-statistics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.quantumrun.com\/consulting\/"},{"@type":"ListItem","position":2,"name":"Companies","item":"https:\/\/www.quantumrun.com\/consulting\/companies\/"},{"@type":"ListItem","position":3,"name":"Pfizer Statistics 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.quantumrun.com\/consulting\/#website","url":"https:\/\/www.quantumrun.com\/consulting\/","name":"Quantumrun Foresight","description":"Thrive from future trends.","publisher":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.quantumrun.com\/consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.quantumrun.com\/consulting\/#organization","name":"Quantumrun Foresight","url":"https:\/\/www.quantumrun.com\/consulting\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/logo\/image\/","url":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2020\/07\/cropped-con-logo-00.png","contentUrl":"https:\/\/www.quantumrun.com\/consulting\/wp-content\/uploads\/2020\/07\/cropped-con-logo-00.png","width":286,"height":55,"caption":"Quantumrun Foresight"},"image":{"@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.quantumrun.com\/consulting\/#\/schema\/person\/5a0afcb410d8e3137f58d5a201809011","name":"Richard Jaimes","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/552ad8a69a374ceb309e1045d345be2d8c30e8a0e8cda42acb1fc357ca381509?s=96&d=mm&r=g","caption":"Richard Jaimes"},"sameAs":["https:\/\/www.quantumrun.com\/consulting"],"url":"https:\/\/www.quantumrun.com\/consulting\/author\/admin-stcons\/"}]}},"_links":{"self":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts\/21385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/comments?post=21385"}],"version-history":[{"count":2,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts\/21385\/revisions"}],"predecessor-version":[{"id":21389,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/posts\/21385\/revisions\/21389"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/media\/21386"}],"wp:attachment":[{"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/media?parent=21385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/categories?post=21385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.quantumrun.com\/consulting\/wp-json\/wp\/v2\/tags?post=21385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}